Ivan Rosas
Overview
Explore the profile of Ivan Rosas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
729
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guo X, Xu K, Wang L, Ding L, Li W, Zhang X, et al.
Front Pharmacol
. 2024 Sep;
15:1433186.
PMID: 39323641
Background: Idiopathic pulmonary fibrosis (IPF) is the result of multiple cycles of epithelial cell injury and fibroblast activation; currently, there is no clear etiology. Increasing evidence suggests that protein metabolism...
2.
Xu K, Ding L, Li W, Wang Y, Ma S, Lian H, et al.
Am J Pathol
. 2024 Jun;
194(8):1478-1493.
PMID: 38849030
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease characterized by pulmonary fibroblast overactivation, resulting in the accumulation of abnormal extracellular matrix and lung parenchymal damage. Although the pathogenesis...
3.
Wang L, Zhao W, Xia C, Ma S, Li Z, Wang N, et al.
Cell Mol Life Sci
. 2023 Dec;
81(1):13.
PMID: 38157020
Idiopathic pulmonary fibrosis (IPF) is a fatal and devastating lung disease of unknown etiology, described as the result of multiple cycles of epithelial cell injury and fibroblast activation. Despite this...
4.
Montesi S, Gomez C, Beers M, Brown R, Chattopadhyay I, Flaherty K, et al.
Am J Respir Crit Care Med
. 2023 Dec;
209(4):362-373.
PMID: 38113442
Despite progress in elucidation of disease mechanisms, identification of risk factors, biomarker discovery, and the approval of two medications to slow lung function decline in idiopathic pulmonary fibrosis and one...
5.
Niu C, Xu K, Hu Y, Jia Y, Yang Y, Pan X, et al.
Respir Res
. 2023 Dec;
24(1):318.
PMID: 38105232
Background: Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease (ILD) with unknown etiology, characterized by sustained damage repair of epithelial cells and abnormal activation of fibroblasts, the underlying...
6.
Wang L, Yuan H, Li W, Yan P, Zhao M, Li Z, et al.
Biochim Biophys Acta Mol Basis Dis
. 2023 Nov;
1870(2):166960.
PMID: 37979225
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease of unknown etiology. The emerging evidence demonstrates that metabolic homeostatic imbalance caused by repetitive injuries of the alveolar...
7.
Kim J, Montesi S, Adegunsoye A, Humphries S, Salisbury M, Hariri L, et al.
Ann Am Thorac Soc
. 2023 Sep;
20(12):1683-1693.
PMID: 37703509
No abstract available.
8.
Wang L, Li Z, Wan R, Pan X, Li B, Zhao H, et al.
Am J Respir Cell Mol Biol
. 2023 Jul;
69(4):456-469.
PMID: 37402274
Idiopathic pulmonary fibrosis (IPF) is a progressive fatal interstitial lung disease without an effective cure. Herein, we explore the role of 3,5,3'-triiodothyronine (T) administration on lung alveolar regeneration and fibrosis...
9.
Blanco-Perez J, Fernandez-Gonzalez-Cuevas L, Cala-Garcia J, Rosas I
Arch Bronconeumol
. 2023 Jul;
59(11):705-706.
PMID: 37394354
No abstract available.
10.
Zhao W, Wang L, Yang J, Chen X, Guo X, Xu K, et al.
Cell Commun Signal
. 2023 Mar;
21(1):56.
PMID: 36915092
Background: Matrix metalloproteinases (MMPs) play important roles in remodeling the extracellular matrix and in the pathogenesis of idiopathic pulmonary fibrosis (IPF). MMP19, which is an MMP, was significantly upregulated in...